Effects of @entity3263 and XXXX on glutamatergic neurotransmission.

@entity1 @entity2227 @entity409 @entity1578 @entity842 @entity99 @entity3263
@entity2227 is the main excitatory neurotransmitter in mammals. Glutamatergic neurotransmission involves several steps, beginning with release of @entity2227 from the presynaptic neuron. @entity2227 in the extracellular space activates @entity2227 receptors present in the synaptic membranes, leading to activation of signal transduction pathways associated with these receptors. To avoid continuous activation of @entity2227 receptors, @entity2227 is removed from the synaptic cleft by specific @entity2227 transporters located mainly on astrocytes. All these steps are tightly modulated under physiological conditions, and alterations of any of the above steps may result in impairment of glutamatergic neurotransmission, leading to neurological alterations. There are studies in the literature reporting alterations in all these steps in @entity3263 and/or @entity1578 . Glutamatergic neurotransmission modulates important cerebral processes. Some of these processes are altered in @entity1 with @entity409 and @entity99 , who show altered sleep-wake patterns, neuromuscular coordination, and decreased intellectual capacity. The alterations in glutamatergic neurotransmission may be responsible for some of these neurological alterations found in @entity99 . The effects of @entity3263 and @entity1578 on different steps of glutamatergic neurotransmission including alterations of @entity2227 concentration in the extracellular fluid in brain, transport and transporters of @entity2227 , the content and function of different types of @entity2227 receptors and signal transduction pathways. Alterations induced by @entity3263 and @entity1578 on the @entity2227 - @entity842 -cGMP pathway in brain may result in changes in long-term potetiation and learning ability.
